TARO-MUPIROCIN OINTMENT

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

MUPIROCIN

Dostupné s:

TARO PHARMACEUTICALS INC

ATC kód:

D06AX09

INN (Mezinárodní Name):

MUPIROCIN

Dávkování:

2%

Léková forma:

OINTMENT

Složení:

MUPIROCIN 2%

Podání:

TOPICAL

Jednotky v balení:

15/30GM

Druh předpisu:

OTC

Terapeutické oblasti:

ANTIBIOTICS

Přehled produktů:

Active ingredient group (AIG) number: 0117081001; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2006-05-05

Charakteristika produktu

_ _
_Taro-Mupirocin Product Monograph _
_Page 1 of 28_
PRODUCT MONOGRAPH
TARO-MUPIROCIN
Mupirocin Ointment USP, 2%
Topical Antibiotic
Taro Pharmaceuticals Inc.
130 East Drive
Brampton, Ontario
L6T 1C1
Date of Preparation:
October 3, 2018
Submission Control No: 218541
_ _
_Taro-Mupirocin Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTION
.....................................................................................................
4
DOSAGE AND ADMINISTRATION
...............................................................................
6
OVERDOSAGE
.................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 7
STORAGE AND STABILITY
...........................................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 9
PART II: SCIENTIFIC INFORMATION
..............................................................................
10
PHARMACEUTICAL INFORMATION
.........................................................................
10
CLINICAL TRIALS
.........................................................................................................
11
DETAILED PHARMACOLOGY
..........................